In 2010, a total of 1327 clinical Escherichia coli isolates were analysed by PCR in 5 hospitals in the 24
5
pAmpC producers and 129 ESBL producers, 4 of which were positive for both the pAmpC and the 94 ESBL genes. The remaining 24 isolates contained neither pAmpC nor ESBL. The prevalence of 95 pAmpC producers was 1.7%. CMY-2 was the most prevalent pAmpC type. Surveillance conducted 96 between 2002 and 2008 in the Kinki region, which includes our study sites, showed that CMY-2 type 97 was most prevalent [11] . However, the prevalence rate from our data (1.7%) seems to be substantially 98 higher (0.1%) than that found previously. One possible explanation for this difference is that the 99 prevalence has varied over time. We did not assess the yearly variation, but the prevalence of pAmpC 100 producers has been increasing; for example, a Spanish study reported that the prevalence increased 101 from 0.04% in 1997 to 1.1% in 2007. The prevalence of ESBL producers was 9.7%. In 2003, inpatient 102 urine collected in 37 hospitals in Japan was studied, and the prevalence was 14% [12] . The SMART 103 surveillance in 2009 reported a diverse prevalence within the Asia-Pacific region that ranged from 104 2.0% in Australia to 65.4% in China [13] . The prevalence of ESBL producers and pAmpC producers 105 were higher in the 2 university hospitals than in the 3 municipal hospitals, which may be associated 106 with the fact that university hospitals had less frequent community-acquired infections and had 107 patients with more severe underlying diseases than municipal hospitals. 108 109 3.2. Antimicrobial susceptibility 110 Table 2 shows the characteristics of the pAmpC producers and the ESBL producers. The 111 most frequent isolation source was urine. All of the isolates were susceptible to imipenem (minimum 112 inhibitory concentration ≤1 g/mL). Almost all of the ESBL producers were judged to be resistant to 113 third-generation cephalosporins by the old CLSI breakpoints (prior to 2010) due to the positive results 114 of the ESBL confirmation test. However, the revised breakpoints classified 66% of ESBL producers 115 as susceptible to ceftazidime. This finding can be explained by the fact that 87% (42/48) of 116 CTX-M-14-producers and 13% (4/31) of CTX-M-15-producers were susceptible to ceftazidime. This 117 phenomenon is worth noting when implementing the revised breakpoints where CTX-M-14 is 118
prevalent. 119
Less than one half of the pAmpC producers were determined to be resistant to 120 6 
Phylogenetic group, CTX-M type, and the ST131 clone isolates 135
Virulent phylogenetic groups B2 and D were prevalent in both pAmpC and ESBL producers. 136
The CTX-M type, which is associated with the international emergence of the O25b-ST131-B2 clone, 137 is now spreading worldwide [1]. CTX-M-15 is most closely associated with the ST131 clone, and thus 138 is the most widely distributed CTX-M subtype. In our study, CTX-M-14 was the most prevalent 139 ESBL, and CTX-M-15 was the second prevalent. Among 125 ESBL producers, 51 isolates of the 140 ST131 clone (41%) were found. CTX-M-27 (41%) and CTX-M-15 (28%) were the most prevalent 141
ESBLs in the ST131 clone isolates; however, CTX-M-27 was rarely found in non-ST131 clone 142
isolates (2%). CTX-M-14 was the most frequent ESBL in non-ST131 isolates (41%). In the previous 143
Japanese nationwide surveillance study, a significant portion of ESBL producers belonged to the 144 clone has doubled, and the distribution of CTX-M types was quite different from that found in a 147 7 previous study. RAPD analysis showed that 135 of the 148 pAmpC or ESBL producers had 148 distinguishable patterns. All of the 13 other isolates belonged to the ST131 clone and were composed 149 of 1 cluster of 3 isolates and 5 clusters of 2 isolates. These results suggest that the ST131 clone is a 150 dominant and unique clone among ESBL producers in our region. 151 The ST131 clone frequently contained genes for TEM-1, OXA-1, aac(6')-Ib-cr, and 152 ciprofloxacin resistance [2] . In our study, the ST131 clone isolates had a higher ciprofloxacin 153 non-susceptible rate (85%) than non-ST131 clone isolates (46%). Table 3 shows all of the 154 ciprofloxacin non-susceptible isolates that had at least 3 mutations in QRDRs. All of the 46 155 ciprofloxacin non-susceptible ST131 clone isolates had double mutations both in GyrA (S83L and 156 D87N) and ParC (S80I and E84V). This genotype was rarely found in the previous study in Asia [10] . IncFIA and IncFIB have been reported [7] . 164 The ST131 clone accounted for only 2 of 19 pAmpC producing-isolates. These two isolates 165 were susceptible to ciprofloxacin. The low prevalence of pAmpC-producing ST131 is consistent with 166 the results of studies from Europe, which found a prevalence of less than 10% [15] . IncI1 was more 167 frequently found in pAmpC producers than in ESBL producers. A Norwegian study reported a high 168 prevalence of IncI1 among CMY-2 producers [15] . 169 170
Conclusion

171
We found that 1.7% of E. coli isolates from clinical specimens were pAmpC producers. 172 Among the ESBL producers, 41% were isolates of the ST131 clone, and these isolates were 173 characterised by ciprofloxacin non-susceptibility with quadruple mutations in QRDRs, the presence of 174 All of the first isolates from each patient that were positive in the ESBL screening test were collected. The prevalences of ESBL producers and 229 pAmpC producers were higher in the 2 university hospitals than in the 3 municipal hospitals (P=0.001 and P=0.13, respectively). The data are presented as the number (%). 235
All in vitro susceptibilities were evaluated using the revised CLSI breakpoints for 2011 except those for the antibiotics labeled "old BP"; for these 236 Table 3 . Molecular mechanism of quinolone resistance among ciprofloxacin non-susceptible ESBL-producing E. coli. 
